For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
|Interested in learning more about our lessons learned in China with COVID-19? Register for our upcoming webinar on April 23.|
Return to the new normal
For Parexel’s teams in China dealing with the COVID-19 pandemic, the return to the new normal feels like a ‘two-foot’ approach – one foot in the present, one in the future. The COVID-19 crisis is spurring the acceleration of innovations in a heavily regulated, traditionally risk-averse industry.
The COVID-19 crisis clearly demonstrated vulnerabilities in traditional clinical trials processes – from the simple ability of a patient or monitor to visit a site, to the supply chain for investigational therapies, to collecting vital trial data.
Creating a more resilient and patient-friendly clinical trial system
Learnings from COVID-19 have dramatically boosted interest in decentralized clinical trials (DCTs). Sometimes called virtual, remote, or site-less trials, DCTs are designed to reduce the travel burdens faced by patients; increase efficiency by moving from paper-based to electronic records; and reduce the need for in-person site visits.
In China we’re seeing a renewed interest among investigators, sites, and regulators toward DCTs – both fully virtual and hybrid approaches. They see the benefits in reducing the amount of face-to-face interaction required (social distancing in a clinical setting) and the time and cost of traveling.
Traveling 400 kilometers each way for a site visit
We discovered a brilliant example of the travel burden put on patients in a review of the impact of COVID-19 on a Parkinson’s disease study in China. A patient in that study had been traveling 400 kilometers each way for a site visit. Imagine how much easier his or her life would be if we could reduce those visits, even one, by using remote techniques.
In February, Parexel commissioned independent research to get the biopharma industry’s view on the benefits and barriers of DCTs. Here’s what we learned:
The biggest benefit: Improved patient experience
The biggest barrier: Validated virtual technologies
It’s clear that COVID-19 is accelerating the move toward DCTs and related or other remote processes, such as site initiation, source document verification and DDM (data-driven monitoring).
Real-world studies in the age of COVID-19
Real-world studies (RWS) are another tool that is gaining interest as a result of the pandemic. We are working with clients to use RWS to speed the analysis of already approved products for possible efficacy against COVID-19. These types of studies augment rigorous but time-consuming randomized clinical trials and observational-type compassionate use of investigational therapies on severely ill patients.
Flexibility in conducting studies during extreme situations like this, with proper regulatory approval and oversight, demonstrates RWS/RWE’s power to provide insights while allowing doctors and nurses more time to help patients.
Strong leadership is a critical success factor when running multiple types of trials during an outbreak. A prime example is the Ebola PALM study, in which several hundred Ebola trials began within a few weeks' time. The World Health Organization, the National Institutes of Health, and the Democratic Republic of the Congo provided much needed leadership which provided order in the chaos of a rapidly unfolding outbreak.
Wearables and sensors
With the increase in DCTs, we also expect accelerated use of wearable and sensors as a result of COVID-19. They provide benefits in the areas of:
While regulations have not caught up the capabilities of wearables, there’s great potential in the use of wearables for typical endpoint assessments like the six-minute walk test.
This will empower sponsors to make early decisions with efficacy and safety endpoints. Parexel’s Patient Sensor Solutions supports the capture, transmission, and analysis of the vast quantities of data generated by connected sensor and device data while our Scientific Data Organization partners with leading regulatory-grade platforms to house, manage, and interpret real-world data.
The fourth and final article in this series is “Beyond COVID-19: The future of clinical research in a changed world”. It will examination COVID-19’s shock to long-established systems (governmental, healthcare, economic, etc.) and to us as individuals and implications for biopharma.
To learn more about our lessons learned in China with COVID-19, register for our April 23 webinar.